Scynexis Looks For Commercial Partner For Its Lead Infection Treatment

Scynexis Inc SCYX announced a new strategic direction to refocus its resources on the clinical development of ibrexafungerp for severe, hospital-based indications.
The company expects its first approval in the hospital setting in 2024.
The company intends to out-license Brexafemme (ibrexafungerp tablets) for vulvovaginal candidiasis (VVC) and is actively pursuing a U.S. commercialization partner.
Related: Scynexis Touts Positive Data For Ibrexafungerp For Vaginal Infections.
During this process, Scynexis will wind down its promotional activities while keeping Brexafemme on the market and available to patients.
Scynexis will conclude the partnership with its contracted commercial sales partner, Amplity Health, and undertake a workforce reduction. The resulting resources will be redirected to the hospital program, extending the cash runway into Q2 2024.
Scynexis' CEO & President Marco Taglietti will retire as of December 31, 2022.
David Angulo, Chief Medical Officer since 2015, will become President & CEO, effective January 1, 2023.
Ivor Macleod will join Scynexis as CFO on October 24.
Price Action: SCYX shares are down 6.12% at $2.76 on the last check Thursday.

Momentum9.48

Growth19.15

QualityNot Available

Value48.15

Short

Medium

Long